Ozempic for Type 1 Diabetes: Is It Approved And Does It Actually Work?

Here’s a question that tens of thousands of people living with type 1 diabetes are actively asking their doctors right now: Can I use Ozempic?

It’s not a casual question. For people managing type 1 diabetes, the daily work of blood sugar control every meal, every workout, every stressful meeting is relentless. So when a drug making headlines for its remarkable glucose and weight effects becomes the most talked about medication in a generation, it’s completely reasonable to ask whether it belongs in your treatment toolkit.

The short answer: Ozempic is not FDA approved for type 1 diabetes. But that’s not the end of the story not by a long shot. Here’s what the most current research actually says.

What Is Ozempic, and How Does It Work?

Ozempic (semaglutide) is a once weekly injectable GLP 1 receptor agonist made by Novo Nordisk. It was FDA approved in 2017 for type 2 diabetes management, and has since received additional approvals for cardiovascular risk reduction and, most recently in January 2025, for slowing the progression of chronic kidney disease in adults with type 2 diabetes.

Its mechanism is elegant: it mimics a naturally occurring gut hormone (GLP 1) that signals the pancreas to release insulin when blood sugar rises, tells the liver to reduce glucose output, slows gastric emptying, and reduces appetite. The result is improved blood sugar control, reduced insulin demand, and meaningful weight loss.

For type 2 diabetes where the pancreas still produces some insulin this mechanism is a near perfect fit. For type 1 diabetes, where the pancreas produces little to no insulin at all, the picture gets more complicated. But also more interesting.

If you want to understand how Ozempic compares to other GLP 1 medications, here’s a clear breakdown of Ozempic vs. Wegovy.

The FDA’s Position: Not Approved But Here’s Why That Matters Less Than You Think

The FDA’s official prescribing label is explicit: Ozempic is not indicated for type 1 diabetes and is not a substitute for insulin. Full stop.

This isn’t a bureaucratic technicality. The concern is real: in type 1 diabetes, suppressing glucagon (which GLP 1 drugs do) without adequate insulin coverage can raise the risk of diabetic ketoacidosis (DKA), a life threatening complication. GLP 1 medications reduce glucagon release the same hormone that normally counteracts hypoglycemia which means the safety margin is thinner in people who depend entirely on exogenous insulin.

That said, “not FDA approved” means there are no completed large scale regulatory trials not that the drug doesn’t work or is inherently dangerous in this population. Off label prescribing is legal, common, and sometimes medically justified when evidence supports it. And in the case of Ozempic for type 1 diabetes, the evidence is building fast.

What Does the 2025 Research Actually Show?

This is where it gets genuinely compelling.

The landmark IU School of Medicine trial (2025): Published in NEJM Evidence, this was the first randomized controlled clinical trial to examine semaglutide specifically in people with type 1 diabetes. Led by Dr. Viral Shah at Indiana University, the study enrolled adults with type 1 diabetes who used automated insulin delivery (AID) systems and had a BMI of 30 or higher. Results showed that weekly semaglutide improved time spent in the target blood sugar range and produced significant weight loss compared to placebo. Critically, there were no cases of severe hypoglycemia or diabetic ketoacidosis during the trial.

McGill University randomized crossover trial (published January 2025 in Nature Medicine): This double blind trial tested semaglutide as an add on to automated insulin delivery in type 1 diabetes adults. Semaglutide increased time in range by a mean of 4.8 percentage points compared to placebo a clinically meaningful improvement without increasing time below safe glucose thresholds. Insulin requirements also dropped, meaning patients needed less insulin overall.

Real world two year data (2025): A Saudi Arabian real world study published in Journal of Diabetes Complications tracked adults with type 1 diabetes on adjunct semaglutide for two years. Results showed improvements in HbA1c and continuous glucose monitoring outcomes.

The pattern: Across multiple studies, semaglutide in type 1 diabetes consistently shows three things better glucose control, reduced insulin requirements, and weight loss without increasing hypoglycemia risk when used alongside modern insulin delivery technology. The researchers behind the IU trial have explicitly called for larger regulatory trials so this could move toward formal FDA approval.

For context on the broader side effect profile of Ozempic and strategies for managing nausea, those apply regardless of diabetes type.

Who Might Be a Candidate and Who Should Not Use It

Current evidence points most clearly to a specific type 1 diabetes profile:

Potentially better candidates:

• Adults with type 1 diabetes and significant overweight or obesity (BMI ≥ 30)
• People already using an automated insulin delivery system
• Those with persistent HbA1c above target despite optimized insulin therapy
• Individuals with type 1 diabetes and insulin resistance (more common than most realize, especially in overweight individuals)

Reasons to proceed with extreme caution or avoid:

• History of diabetic ketoacidosis (DKA) or high DKA risk
• Lean individuals with type 1 diabetes who don’t carry excess weight
• Not using an automated insulin delivery or continuous glucose monitoring system
• Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• Pregnancy or breastfeeding

This is also not a medication to start based on a social media recommendation. The safety risks in type 1 diabetes are real and require close clinical supervision. If you’re curious whether you’re even a candidate for GLP 1 therapy of any kind, here’s a full guide to who is NOT a good candidate for GLP 1 medications.

What This Means for Your Diabetes Management Right Now

The most important thing to understand: Ozempic does not replace insulin in type 1 diabetes ever. No matter what the research shows about its adjunct benefits, every person with type 1 diabetes still requires insulin therapy. That is not negotiable.

What the research does suggest is that for the right patient, semaglutide may meaningfully improve glycemic stability, reduce the total insulin dose needed, and address weight gain a genuine and often unspoken struggle for many people with type 1 diabetes.

Here are the most actionable steps you can take today:

1. Ask your endocrinologist directly whether semaglutide is appropriate given your specific A1c, weight, insulin delivery method, and DKA history.
2. Understand your insulin delivery setup. Current evidence is strongest for people using closed loop or automated insulin delivery systems.
3. Monitor your blood sugar more closely if you do trial semaglutide off label appetite suppression can affect carbohydrate intake and insulin needs significantly.
4. Know the DKA warning signs. Nausea, vomiting, abdominal pain, and fruity smelling breath warrant immediate medical evaluation.
5. Get the full metabolic picture. For many people with type 1 diabetes, insulin resistance is an underappreciated driver of poor glucose control and that’s a separate conversation worth having.

Conclusion: The Science Is Moving Faster Than the Approval Process

Ozempic for type 1 diabetes isn’t FDA approved, and the safety considerations are real. But dismissing it outright ignores a growing body of 2025 evidence showing it can meaningfully improve glucose control and quality of life for a specific subset of type 1 patients especially those with obesity using advanced insulin delivery technology.

The researchers who are conducting these trials aren’t working on a whim. They believe formal approval is coming. In the meantime, if you have type 1 diabetes and are wondering whether semaglutide belongs in your care plan, that’s a conversation to have with a clinician who actually knows your full metabolic picture not an algorithm, not a TikTok video.

At AK Twisted Wellness, we provide whole person metabolic evaluations, GLP 1 consultations, and telehealth access for patients navigating complex hormonal and metabolic questions. Whether you’re managing type 1 or type 2 diabetes, weight challenges, or hormonal imbalances, we build real plans for real biology.

Visit aktw.life or call (520) 710 8805. Telehealth available.

Frequently Asked Questions

1. Is Ozempic approved for type 1 diabetes? No. As of 2026, Ozempic (semaglutide) is FDA approved only for type 2 diabetes, cardiovascular risk reduction, and chronic kidney disease in adults with type 2 diabetes. Its prescribing label explicitly states it is not for use in people with type 1 diabetes. However, off label use is being studied actively, and multiple 2025 clinical trials have produced promising results.

2. Can Ozempic replace insulin in type 1 diabetes? Absolutely not, and this cannot be overstated. People with type 1 diabetes require insulin to survive there is no substitute. Ozempic has only been studied as an adjunct (add on) to insulin therapy in type 1 diabetes, never as a replacement. Taking Ozempic without insulin in type 1 diabetes could be life threatening.

3. What did the 2025 clinical trials show about semaglutide in type 1 diabetes? Two significant 2025 trials one from Indiana University and one from McGill University found that semaglutide improved time spent in target blood sugar range, reduced insulin requirements, and promoted weight loss in adults with type 1 diabetes using automated insulin delivery systems. Neither trial observed severe hypoglycemia or diabetic ketoacidosis, though the studies were small and short term.

4. What is the biggest safety risk of Ozempic in type 1 diabetes? The primary concern is diabetic ketoacidosis (DKA). GLP 1 medications suppress glucagon the hormone that helps the body recover from low blood sugar which can increase DKA risk in people dependent on insulin. This is why current research has focused specifically on people using automated insulin delivery systems, which can adjust insulin delivery more precisely. Anyone considering off label semaglutide use with type 1 diabetes must have this conversation with their doctor.

5. Are there other GLP 1 medications being studied for type 1 diabetes? Yes. Tirzepatide (Mounjaro/Zepbound), a dual GLP 1/GIP agonist, is also being investigated for type 1 diabetes. Early data show even greater weight loss than semaglutide between 10–20 kg in some studies with significant reductions in insulin dose requirements. Neither tirzepatide nor semaglutide currently carries FDA approval for type 1 diabetes. Learn more about how GLP 1 medications compare here.

6. Can AK Twisted Wellness help with GLP 1 therapy and metabolic health? Yes. Our team provides comprehensive metabolic and hormonal evaluations, GLP 1 medication consultations, and personalized care plans for patients navigating weight, blood sugar, and hormonal health challenges. We offer telehealth services so you can access expert guidance wherever you are. Visit aktw.life or call (520) 710 8805 to schedule your consultation.

References

1. U.S. Food & Drug Administration / Novo Nordisk. (2025). Ozempic (semaglutide) Prescribing Information Full Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
2. Indiana University School of Medicine. (2025). Type 2 Diabetes Drug Improves Weight Loss, Blood Sugar in Certain Type 1 Patients with Obesity. https://medicine.iu.edu/news/2025/06/semaglutide type1 diabetes clinical trial
3. Pasqua, M.R., Tsoukas, M.A., et al. (2025). Subcutaneous Weekly Semaglutide with Automated Insulin Delivery in Type 1 Diabetes: A Double Blind, Randomized, Crossover Trial. Nature Medicine. https://www.nature.com/articles/s41591 024 03463 z
4. Madsbad, S. (2025). Treatment of People with Type 1 Diabetes with Semaglutide or Tirzepatide Relevant in the Future? Medical Research Archives. https://esmed.org/MRA/mra/article/view/6925
5. Novo Nordisk. (2025). FDA Approves Ozempic to Reduce Risk of Kidney Disease Worsening in Adults with Type 2 Diabetes and CKD. https://www.novonordisk us.com/media/news archive/news details.html?id=915253
6. StatPearls / NCBI Bookshelf. (2024). Semaglutide Indications, Pharmacology, and Off Label Uses. https://www.ncbi.nlm.nih.gov/books/NBK603723/
7. JAMA Network. (2025). FDA Approves Semaglutide to Reduce Risk of Kidney Disease Progression. https://jamanetwork.com/journals/jama/fullarticle/2831055
8. American Diabetes Association. (2025). Standards of Medical Care in Diabetes. https://diabetesjournals.org/care/issue/48/Supplement_1
9. ClinicalTrials.gov. (2025). ADJUnct Semaglutide Treatment in Type 1 Diabetes (ADJUST). https://clinicaltrials.gov/study/NCT05537233
10. PubMed / NCBI. (2025). Subcutaneous Weekly Semaglutide with Automated Insulin Delivery in T1D. https://pubmed.ncbi.nlm.nih.gov/39794615/
    

Disclaimer: This content is for informational and educational purposes only and does not constitute medical, legal, or financial advice. Reading this article does not create a patient provider relationship. GLP 1 medications carry real risks that require individualized medical evaluation never start, stop, or adjust any medication without consulting a qualified healthcare provider. For questions about AK Twisted Wellness services, visit aktw.life or call (520) 710 8805.